Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Dropouts are common events in longitudinal studies in depression. Ignoring missing information may lead to biased and inconsistent assessment of study results. A non-linear model was recently developed to describe the time-course of HAMD-17 clinical score in the placebo arms of antidepressant clinical trials. In this paper we complemented this model by introducing an informative dropout component to jointly estimate HAMD-17 time-course and dropout mechanism. The aims of this work were to: (a) characterise typical placebo response in depression trials in presence of dropouts, (b) explore which dropout mechanism better describe the time-varying probability of a subject to dropout from the trial, and (c) define a framework for the development of clinical trial simulation in depression. A meta-analytic approach was used on placebo data collected in 6 clinical trials including 695 subjects suffering from Major Depressive Disorders. Alternative hypotheses for "missingness" were evaluated using different hazard models. The "Missing Not At Random" performed statistically (p<0.01) better than "Missing At Random", that in turn performed better (p<0.01) than "Missing Completely At Random" model. This finding provided new insights on the validity of the analyses currently used in many longitudinal clinical trials to support the registration of a new medicinal product.

[1]  M. Kenward,et al.  Informative Drop‐Out in Longitudinal Data Analysis , 1994 .

[2]  Mark E. Sale,et al.  A Joint Model for Nonlinear Longitudinal Data with Informative Dropout , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[3]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[4]  Geert Molenberghs,et al.  Assessing and interpreting treatment effects in longitudinal clinical trials with missing data , 2003, Biological Psychiatry.

[5]  A. Nierenberg,et al.  Evolution of remission as the new standard in the treatment of depression. , 1999, The Journal of clinical psychiatry.

[6]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[7]  N M Laird,et al.  Model-based approaches to analysing incomplete longitudinal and failure time data. , 1997, Statistics in medicine.

[8]  M. Wulfsohn,et al.  A joint model for survival and longitudinal data measured with error. , 1997, Biometrics.

[9]  Sati Mazumdar,et al.  Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods , 2004, Psychiatry Research.

[10]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[11]  Craig H. Mallinckrodt,et al.  Type I Error Rates from Mixed Effects Model Repeated Measures Versus Fixed Effects Anova with Missing Values Imputed Via Last Observation Carried Forward , 2001 .

[12]  S. Hollon,et al.  Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. , 2007, The American journal of psychiatry.

[13]  C H Mallinckrodt,et al.  ACCOUNTING FOR DROPOUT BIAS USING MIXED-EFFECTS MODELS , 2001, Journal of biopharmaceutical statistics.

[14]  J. Feighner,et al.  Double-blind comparison of bupropion and fluoxetine in depressed outpatients. , 1991, The Journal of clinical psychiatry.

[15]  D. Hedeker.  A mixed‐effects multinomial logistic regression model , 2003, Statistics in medicine.

[16]  K. Krishnan,et al.  Is there a Definition of Remission in Late-Life Depression that Predicts Later Relapse? , 2004, Neuropsychopharmacology.

[17]  B. Pitrosky,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder , 2007, International clinical psychopharmacology.

[18]  Raymond J. Carroll,et al.  Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process , 1988 .

[19]  B. Mulsant,et al.  Statistical analysis of longitudinal psychiatric data with dropouts. , 2007, Journal of psychiatric research.

[20]  J. Krystal,et al.  Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. , 2004, Archives of general psychiatry.

[21]  M. Osterheider,et al.  Three types of early termination of antidepressant drug treatment , 1993, International clinical psychopharmacology.

[22]  Sati Mazumdar,et al.  Use of OSWALD for analyzing longitudinal data with informative dropout , 2007, Comput. Methods Programs Biomed..

[23]  J. Feighner,et al.  A Double‐Blind Comparison of Paroxetine With Imipramine in the Long‐Term Treatment of Depression , 1993, Journal of clinical psychopharmacology.

[24]  E Niclas Jonsson,et al.  More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.

[25]  B. Pollock,et al.  Intent-to-treat analysis for clinical trials: use of data collected after termination of treatment protocol. , 2002, Journal of psychiatric research.

[26]  Geert Molenberghs,et al.  Analyzing incomplete longitudinal clinical trial data. , 2004, Biostatistics.

[27]  M. Fava,et al.  Early drop-outs, late drop-outs and completers Differences in the continuation phase of a clinical trial , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.